✕
Use of the generic versions of directly-acting antiviral (DAA) drugs that are available in India to treat hepatitis C virus (HCV) infection can increase lifespan while reducing lifetime health care costs, says a study. Compared with no DAA treatment, use of the generic drugs in HCV-infected Indian patients would increase life expectancy by more than eight years while reducing lifetime health care costs by more than $1,300 (Rs. 116,442) per person, said the study published in the journal PLOS ONE.
First introduced in 2011, DAAs such as sofosbuvir (Sovaldi) and ledipasvir (which is combined with sofosbuvir in Harvoni) have proven to be remarkably successful in the battle against HCV infection, with cure rates exceeding 95 per cent.
In developed countries, treatment with DAAs is very expensive — reaching nearly $65,000 in the US — although it meets standards for cost effectiveness.
http://morungexpress.com/beneficial-generic-hepatitis-c-drugs-available-india/
First introduced in 2011, DAAs such as sofosbuvir (Sovaldi) and ledipasvir (which is combined with sofosbuvir in Harvoni) have proven to be remarkably successful in the battle against HCV infection, with cure rates exceeding 95 per cent.
In developed countries, treatment with DAAs is very expensive — reaching nearly $65,000 in the US — although it meets standards for cost effectiveness.
http://morungexpress.com/beneficial-generic-hepatitis-c-drugs-available-india/
How beneficial are generic hepatitis C drugs available in India? - The Morung Express
Use of the generic versions of directly-acting antiviral (DAA) drugs that are available in India to treat hepatitis C virus (HCV) infection can increase lifespan while reducing lifetime health care costs, says a study.
Like
Comment
Share
